Long-term results of intravesical bacillus calmette-guérin therapy for stage T1 superficial bladder cancer

Brake, M.; Loertzer, Hagen; Horsch, R; Keller, H.

doi:10.1016/s0090-4295(99)00591-9

Cited by 57 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large number of prospective studies showed a significant decrease in recurrence rates through the use of BCG. However, prevention of the progress of tumor disease was not recorded [20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Survival Rates after Radical Cystectomy according to Tumor Stage of Bladder Carcinoma at First Presentation

et al. 2004

View full text Add to dashboard Cite

Introduction: The aim of this study was to establish to what extent the survival rates of muscle-invasive bladder carcinoma are influenced by the tumor stage at initial presentation. Patients and Methods: This study examined the clinical course of 230 patients who underwent radical cystectomy for bladder carcinoma from 1992 to 2002. The patients were divided into three groups according to the histological results of the initial and final transurethral tumor resection (TURB). In group 1 (n = 41) radical cystectomy was carried out for a superficial bladder carcinoma which had a high likelihood of progressing. Group 2 (n = 57) consisted of patients who displayed a superficial tumor stage when they first presented and developed progressive muscle-invasive bladder carcinoma under conservative treatment. Group 3 (n = 132) was made up of patients who were already at the muscle-invasive tumor stage in the course of primary TURB. The histopathological characteristics of all transurethral tumor resections and radical cystectomy were recorded. Progression-free survival and overall survival in the three groups were then compared. Results: The average patient age when cystectomy was carried out was 63.9 (35–80) years and the average follow-up period was 38 months. An average of 2.3 (1–16) transurethral tumor resections were carried out before radical cystectomy (median = 1). Progression-free survival and overall survival of all 230 patients was 54 and 50%, respectively, after 5 years. The best result was a 74% progression-free 5-year survival rate with organ-confined lymph node-negative tumors (n = 106) which was statistically significant (p = 0.0004) compared to the progression-free 5-year survival rate of 50% for non-organ-confined, lymph node-negative tumors (n = 64). Lymph node-positive patients achieved a progression-free survival rate of 21% after 5 years regardless of the tumor infiltration. Patients in group 1 achieved a progression-free 5-year survival rate of 77% and an overall survival rate of 63% after 5 years. In group 2 patients achieved a progression-free survival rate of 51% after 5 years and an overall survival rate of 50%. In the case of primary muscle invasion (group 3), progression-free survival and overall survival were 49 and 46%, respectively, after 5 years. There was no significant difference between groups 2 and 3 with regard to their progression-free or overall survival rates (p > 0.35). However, both groups displayed a significantly poorer progression-free and overall survival rate compared with group 1 (p < 0.01). Conclusion: Our results show that superficial bladder carcinoma with tumor progress to muscle invasion does not have a better prognosis after radical cystectomy than initial muscle-invasive bladder carcinoma. Survival rates in this group can only be improved by singling out patients on the basis of risk factors at an earlier stage and carrying out a cystectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival Rates after Radical Cystectomy according to Tumor Stage of Bladder Carcinoma at First Presentation

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Although the anticancer mechanisms of BCG are not totally understood, they are generally considered to involve immunological reactions. [14][15][16][17][18] Clinically, superficial bladder cancer is highly sensitive to BCG, [19][20][21][22] and it is generally well established that stimulation of the immune system exerts only beneficial effects on tumor development. In contrast, anticancer drugs may sometimes act as tumor-promoting agents, both in animal experiments 23 and in human cases, 24 at least partly as a result of immunological damage.…”

Section: Discussionmentioning

confidence: 99%

Bacillus Calmette?Guerin-refractory superficial bladder cancers: focus on pretreatment episodes

Okamura

Akita

Tozawa

et al. 2003

International Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Diğer 24 hastaya tekrarlayan TUR sonrası BCG verilmiş ve %79 başarı elde edilmiştir. Bu sonuçlar diğer benzer çalışmalar ile desteklenmiştir (30). Soloway ve ark.…”

Section: Basillus Calmette Guerin Tedavisi Geç Rekürrenslerunclassified

Yüksek Riskli Kasa İnvaze Olmayan Mesane Kanserinde Erken Sistektomi mi yoksa Mesane Koruyucu Tedavi mi Tercih edelim?

Batur¹,

Sözen²

2014

uob

View full text Add to dashboard Cite

show abstract

Long-term results of intravesical bacillus calmette-guérin therapy for stage T1 superficial bladder cancer

Cited by 57 publications

References 23 publications

Survival Rates after Radical Cystectomy according to Tumor Stage of Bladder Carcinoma at First Presentation

Survival Rates after Radical Cystectomy according to Tumor Stage of Bladder Carcinoma at First Presentation

Bacillus Calmette?Guerin-refractory superficial bladder cancers: focus on pretreatment episodes

Yüksek Riskli Kasa İnvaze Olmayan Mesane Kanserinde Erken Sistektomi mi yoksa Mesane Koruyucu Tedavi mi Tercih edelim?

Contact Info

Product

Resources

About